Get the Stockscreener App
0.86
1.37%
+0.0116
Scilex Holding Company stock is currently priced at $0.86, with a 24-hour trading volume of 370.81K.
It has seen a +1.37% increased in the last 24 hours and a -44.16% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.8578 pivot point. If it approaches the $0.8809 resistance level, significant changes may occur.
Previous Close:
$0.8484
Open:
$0.882
24h Volume:
370.81K
Market Cap:
$104.16M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-1.4305
EPS:
-0.6012
Net Cash Flow:
$-21.04M
1W Performance:
-2.33%
1M Performance:
-44.16%
6M Performance:
-47.56%
1Y Performance:
-84.36%
1D Range:
$0.8401
$0.8929
52W Range:
$0.8002
$8.3699
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
650-516-4310
Address
960 San Antonio Road, Palo Alto
Scilex Holding Company Stock (SCLX) Latest News
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
GlobeNewswire Inc.
Scilex Holding Company Announces $15 Million Registered Direct Offering
GlobeNewswire Inc.
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
GlobeNewswire Inc.
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
GlobeNewswire Inc.
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
GlobeNewswire Inc.
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
GlobeNewswire Inc.
Scilex Holding Company Stock (SCLX) Financials Data
Scilex Holding Company (SCLX) Revenue 2024
SCLX reported a revenue (TTM) of $46.74 million for the quarter ending December 31, 2023, a +22.90% rise year-over-year.
Scilex Holding Company (SCLX) Net Income 2024
SCLX net income (TTM) was -$114.33 million for the quarter ending December 31, 2023, a -389.35% decrease year-over-year.
Scilex Holding Company (SCLX) Cash Flow 2024
SCLX recorded a free cash flow (TTM) of -$21.04 million for the quarter ending December 31, 2023, a +1.04% increase year-over-year.
Scilex Holding Company (SCLX) Earnings per Share 2024
SCLX earnings per share (TTM) was -$1.29 for the quarter ending December 31, 2023, a -646.53% decline year-over-year.
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
0.35%
0.91%
Cap:
|
Volume (24h):